Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Vitalhub Corp T.VHI

Alternate Symbol(s):  VHIBF

VitalHub Corp. is a software company. It offers software for health and human service providers designed to simplify the user experience and optimize outcomes. It offers a comprehensive suite of software-as-a-service solutions, which include electronic health record (EHR), case management, care coordination, and optimization; patient flow, operational visibility, and patient journey optimization; and workforce automation and compliance. Its solutions include Alamac, Beautiful Information, Hicom, Intouch with Health, MCAP, Oculys, SHREWD, Synopsis, B Care, CaseWORKS, Pirouette, S12 Solutions, OrderWise and TREAT. Its clients include hospitals, regional health authorities, mental health and addictions services providers for children and adults, long-term care facilities, correctional services, and community and social services providers. It also offers transitions of care technology internationally. It serves clients across Canada, the USA, the UK, Australia, the Middle East, and Europe.


TSX:VHI - Post by User

Post by theinvestor22on May 11, 2023 10:06pm
253 Views
Post# 35444588

Q1 2023 results

Q1 2023 results
Another good quarter, keeping in mind that the same quarter last year had in it a big amount of perpetual license revenue which is one time in nature.  If you adjust for that, Q1 of 2022 would likely have been pretty mediocre.
 
I usually remove forex and business acq./etc expenses to compare quarters.  Doing that and adjusting the perpetual license line to me makes this latest quarter the best yet.
 
Having said that, the issue of finding synergies in G&A and R&D expenses remains.  The company, to their credit, has acknowledged that.
 
In terms of ARR, once again there is very good progress on that front.
 
There is a good chart in the MD&A on page 9 (showing revenue and EBITDA growth and clearly showing the Q1 2022 revenue blip due to the high amount of perpetual licenses) and another couple of good charts on page 12 showing organic vs. acq growth.
 
This is going to take a while, but we're getting there... 
<< Previous
Bullboard Posts
Next >>